GlassScriptPhysician profile
Katina D Smith
NPI 1245896893
$9,128.88
in general payments reported to CMS, 2019-2025
25 companies · $4,090 in 2025
The $4,090 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $604 · 2022: $969 · 2023: $1,184 · 2024: $2,282 · 2025: $4,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,489 · Consulting Fee: $2,031 · Education: $36.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,488.67 |
| Consulting Fee | $2,031.16 |
| Education | $36.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $2,334.12 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $1,388.83 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,267.86 | 2021-2025 | Tavneos, Krystexxa, Aranesp |
| Glaxosmithkline, LLC. | $592.27 | 2022-2025 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $515.94 | 2021-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $453.70 | 2023-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $380.32 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $333.56 | 2022-2025 | Acthar, Terlivaz |
| Novartis Pharmaceuticals Corporation | $269.04 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $247.87 | 2021-2025 | Jynarque |
| Ardelyx, INC. | $191.03 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Opko Pharmaceuticals, LLC | $180.26 | 2021-2025 | Rayaldee |
| Novo Nordisk INC | $178.02 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $175.08 | 2024-2025 | Jardiance |
| Vantive US Healthcare LLC | $168.27 | 2025 | Renal - Acute |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $114.76 | 2021-2023 | Velphoro |
| Akebia Therapeutics INC | $78.32 | 2021-2024 | Auryxia, Vafseo |
| Scpharmaceuticals INC. | $72.53 | 2025 | |
| Horizon Therapeutics Plc | $40.82 | 2022-2023 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $38.04 | 2025 | |
| Cormedix INC. | $29.87 | 2024 | Defencath |
| Ani Pharmaceuticals, INC. | $23.69 | 2024 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $20.88 | 2023 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.89 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $14.91 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katina Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.